EVO
Price
$10.12
Change
-$0.23 (-2.22%)
Updated
Sep 25, 6:59 PM EST
44 days until earnings call
TAK
Price
$15.96
Change
+$0.12 (+0.76%)
Updated
Sep 25, 12:04 PM EST
31 days until earnings call

Compare predictions EVO vs TAK

Header iconEVO vs TAK Comparison
Open Charts EVO vs TAKBanner chart's image
Evotec SE
Price$10.12
Change-$0.23 (-2.22%)
Volume$11.24K
CapitalizationN/A
Takeda Pharmaceutical
Price$15.96
Change+$0.12 (+0.76%)
Volume$796
CapitalizationN/A
View a ticker or compare two or three
EVO vs TAK Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
EVO vs. TAK commentary
Sep 26, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVO is a Hold and TAK is a Sell.

COMPARISON
Comparison
Sep 26, 2023
Stock price -- (EVO: $10.35 vs. TAK: $15.84)
Brand notoriety: EVO and TAK are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EVO: 61% vs. TAK: 60%
Market capitalization -- EVO: $3.65B vs. TAK: $49.6B
EVO [@Pharmaceuticals: Other] is valued at $3.65B. TAK’s [@Pharmaceuticals: Other] market capitalization is $49.6B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $81.33B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVO’s FA Score shows that 1 FA rating(s) are green whileTAK’s FA Score has 1 green FA rating(s).

  • EVO’s FA Score: 1 green, 4 red.
  • TAK’s FA Score: 1 green, 4 red.
According to our system of comparison, TAK is a better buy in the long-term than EVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVO’s TA Score shows that 5 TA indicator(s) are bullish while TAK’s TA Score has 6 bullish TA indicator(s).

  • EVO’s TA Score: 5 bullish, 4 bearish.
  • TAK’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both EVO and TAK are a good buy in the short-term.

Price Growth

EVO (@Pharmaceuticals: Other) experienced а -15.16% price change this week, while TAK (@Pharmaceuticals: Other) price change was -2.94% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.13%. For the same industry, the average monthly price growth was +18.58%, and the average quarterly price growth was +10.13%.

Reported Earning Dates

EVO is expected to report earnings on Nov 08, 2023.

TAK is expected to report earnings on Oct 26, 2023.

Industries' Descriptions

@Pharmaceuticals: Other (+3.13% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
A.I.dvisor published
a Summary for EVO with price predictions.
OPEN
A.I.dvisor published
a Summary for TAK with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
TAK($49.6B) has a higher market cap than EVO($3.65B). EVO has higher P/E ratio than TAK: EVO (476.19) vs TAK (24.57). EVO YTD gains are higher at: 27.936 vs. TAK (1.538). TAK has higher annual earnings (EBITDA): 1.15T vs. EVO (-77.17M). TAK has more cash in the bank: 369B vs. EVO (633M). EVO has less debt than TAK: EVO (492M) vs TAK (4.75T). TAK has higher revenues than EVO: TAK (4.11T) vs EVO (798M).
EVOTAKEVO / TAK
Capitalization3.65B49.6B7%
EBITDA-77.17M1.15T-0%
Gain YTD27.9361.5381,816%
P/E Ratio476.1924.571,938%
Revenue798M4.11T0%
Total Cash633M369B0%
Total Debt492M4.75T0%
FUNDAMENTALS RATINGS
EVO vs TAK: Fundamental Ratings
EVO
TAK
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
19
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9143
PRICE GROWTH RATING
1..100
5948
P/E GROWTH RATING
1..100
275
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TAK's Valuation (19) in the Pharmaceuticals Major industry is significantly better than the same rating for EVO (94) in the null industry. This means that TAK’s stock grew significantly faster than EVO’s over the last 12 months.

TAK's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as EVO (100) in the null industry. This means that TAK’s stock grew similarly to EVO’s over the last 12 months.

TAK's SMR Rating (43) in the Pharmaceuticals Major industry is somewhat better than the same rating for EVO (91) in the null industry. This means that TAK’s stock grew somewhat faster than EVO’s over the last 12 months.

TAK's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as EVO (59) in the null industry. This means that TAK’s stock grew similarly to EVO’s over the last 12 months.

EVO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for TAK (75) in the Pharmaceuticals Major industry. This means that EVO’s stock grew significantly faster than TAK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EVOTAK
RSI
ODDS (%)
Bullish Trend 4 days ago
86%
Bearish Trend 4 days ago
42%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
51%
Momentum
ODDS (%)
Bearish Trend 4 days ago
65%
Bullish Trend 4 days ago
42%
MACD
ODDS (%)
Bearish Trend 4 days ago
63%
Bullish Trend 4 days ago
51%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
60%
Bearish Trend 4 days ago
51%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
57%
Bullish Trend 4 days ago
43%
Advances
ODDS (%)
Bullish Trend 12 days ago
67%
Bullish Trend 11 days ago
47%
Declines
ODDS (%)
Bearish Trend 5 days ago
74%
Bearish Trend 4 days ago
45%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
47%
Aroon
ODDS (%)
Bullish Trend 4 days ago
61%
Bullish Trend 4 days ago
45%
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ORGS0.630.04
+6.38%
Orgenesis
RYAM2.820.05
+1.81%
Rayonier Advanced Materials
SXC9.72-0.01
-0.10%
Suncoke Energy
ASAI11.65-0.16
-1.35%
Sendas Distribuidora SA
BNTX104.64-1.79
-1.68%
BioNTech SE American Depositary Share

TAK and

Correlation & Price change

A.I.dvisor indicates that over the last year, TAK has been loosely correlated with RDY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if TAK jumps, then RDY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TAK
1D Price
Change %
TAK100%
-0.56%
RDY - TAK
39%
Loosely correlated
-2.08%
DVAX - TAK
31%
Poorly correlated
-0.66%
EVO - TAK
31%
Poorly correlated
+1.37%
PBH - TAK
30%
Poorly correlated
+0.85%
HLN - TAK
28%
Poorly correlated
-1.93%
More